CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that it ranked No. 2 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing tech companies in North America, now in its 32nd year. ImmunityBio grew over 47,000% during 2022 to 2025.“Ranking No. 2 on the Deloitte Technology Fast 500 list reflects the Company’s significant growth and the expanding adoption of ANKTIVA® in the U.S. and globally,” said

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.